losartan has been researched along with Diabetic Angiopathies in 34 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to determine the effect of losartan on transforming growth factor-beta1 (TGF-beta1) plasma levels and urinary albumin excretion (UAE) in patients with type 2 diabetes mellitus, mild hypertension and microalbuminuria." | 9.09 | Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. ( Campistol, JM; Esmatjes, E; Flores, L; Iñigo, P; Lario, S; Ruilope, LM, 2001) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 6.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| " In multivariable Cox analyses, adjusting for randomized treatment, age, sex, race, prior anti-hypertensive therapy, baseline uric acid, serum creatinine and glucose entered as standard covariates, and in-treatment non-HDL cholesterol, Cornell product left ventricular hypertrophy, diastolic and systolic pressure, BMI, hydrochlorothiazide and statin use as time-varying covariates, the lowest quartile of in-treatment HDL remained associated with a nearly 9-fold increased risk of new diabetes (hazard ratio 8." | 5.17 | In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM; Wiik, BP, 2013) |
| "To compare the effects of losartan and amlodipine on myocardial structure and function in hypertensive patients with Type 2 diabetes and left ventricular hypertrophy." | 5.16 | Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. ( Corradi, L; Derosa, G; Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2012) |
| "These results suggest that in type 2 diabetes with overt nephropathy, 24-h blood pressure regulation alone is inadequate to reduce macroalbuminuria and additional effects of losartan are crucial for antiproteinuric action." | 5.11 | Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. ( Ando, D; Hirawa, N; Tochikubo, O; Umemura, S; Yasuda, G, 2005) |
| "5 mg of hydrochlorothiazide, in 90 type 2 diabetic patients with microalbuminuria and blood pressure > 130/85 mmHg, receiving losartan 50 mg as initial treatment during 4 weeks." | 5.10 | Losartan titration versus diuretic combination in type 2 diabetic patients. ( de Pablos-Velasco, PL; Esmatjes, JE; Fernandez-Vega, F; Lopez de la Torre, ML; Pazos Toral, F; Pozuelo, A; Ruilope, LM, 2002) |
| "Twenty-one subjects with hypertension and AER between 10 and 200 microg/min were randomized to receive either 50 mg losartan daily (n = 11) or placebo (n = 10)." | 5.10 | Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. ( Akdeniz, A; Cooper, ME; Gilbert, RE; Houlihan, CA; Jerums, G; Tsalamandris, C, 2002) |
| "The aim of the present study was to determine the effect of losartan on transforming growth factor-beta1 (TGF-beta1) plasma levels and urinary albumin excretion (UAE) in patients with type 2 diabetes mellitus, mild hypertension and microalbuminuria." | 5.09 | Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. ( Campistol, JM; Esmatjes, E; Flores, L; Iñigo, P; Lario, S; Ruilope, LM, 2001) |
| "Compared with other angiotensin-receptor blockers, telmisartan and valsartan were both associated with a lower risk of admission to hospital for acute myocardial infarction, stroke or heart failure among older adults with diabetes and hypertension." | 3.79 | Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. ( Antoniou, T; Camacho, X; Gomes, T; Juurlink, DN; Mamdani, MM; Yao, Z, 2013) |
| " We hypothesized that insulin-induced relaxation and the associated proline-rich tyrosine kinase 2 (Pyk2)/Src/Akt pathway would be abnormal in aortas from the Goto-Kakizaki (GK) type 2 diabetic rat, which exhibits hyperglycemia/insulin resistance, and that losartan treatment of such rats (25 mg·kg(-1)·day(-1) for 2 wk) would correct these abnormalities." | 3.77 | Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats. ( Kamata, K; Kobayashi, T; Matsumoto, T; Nemoto, S; Taguchi, K, 2011) |
| "2,628 adults with type 2 diabetes and nephropathy." | 2.80 | Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St ( Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH, 2015) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 2.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | 2.70 | [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001) |
| "Diabetes (particularly type 2 diabetes) represents a global health problem of epidemic proportions." | 2.43 | Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. ( Burnier, M; Zanchi, A, 2006) |
| "The major goal of treating high blood pressure in this population is to prevent or reduce the likelihood of target-organ damage." | 2.42 | Optimizing target-organ protection in patients with diabetes mellitus: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? ( Lakkis, J; Lu, WX; Weir, MR, 2003) |
| "Arterial hypertension is a major risk factor for microangiopathic diabetic complications and associated with an increased cardiovascular morbidity and mortality." | 2.41 | [Angiotensin II type-1 receptor antagonists and diabetes mellitus]. ( Schernthaner, G; Schnack, C, 2001) |
| "Treatment with losartan 100 and 150 mg lowered GFR by 4 ml/min/1." | 1.31 | Optimal dose of losartan for renoprotection in diabetic nephropathy. ( Andersen, S; Deinum, J; Juhl, TR; Parving, HH; Rossing, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (67.65) | 29.6817 |
| 2010's | 11 (32.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okin, PM | 1 |
| Hille, DA | 1 |
| Wiik, BP | 1 |
| Kjeldsen, SE | 1 |
| Lindholm, LH | 1 |
| Dahlöf, B | 1 |
| Devereux, RB | 1 |
| Cherney, DZ | 1 |
| Zinman, B | 1 |
| Kennedy, CR | 1 |
| Moineddin, R | 1 |
| Lai, V | 1 |
| Yang, S | 1 |
| Miller, JA | 1 |
| Prokopec, SD | 1 |
| Boutros, PC | 1 |
| Scholey, JW | 1 |
| Reich, HN | 1 |
| Antoniou, T | 1 |
| Camacho, X | 1 |
| Yao, Z | 1 |
| Gomes, T | 1 |
| Juurlink, DN | 1 |
| Mamdani, MM | 1 |
| Schutte, E | 1 |
| Lambers Heerspink, HJ | 2 |
| Lutgers, HL | 1 |
| Bakker, SJ | 1 |
| Vart, P | 1 |
| Wolffenbuttel, BH | 1 |
| Umanath, K | 1 |
| Lewis, JB | 2 |
| de Zeeuw, D | 4 |
| Gansevoort, RT | 1 |
| Marshall, SM | 1 |
| Alosh, M | 1 |
| Huque, MF | 1 |
| Holtkamp, FA | 1 |
| de Graeff, PA | 1 |
| Laverman, GD | 1 |
| Berl, T | 1 |
| Remuzzi, G | 2 |
| Packham, D | 1 |
| Parving, HH | 4 |
| Fogari, R | 1 |
| Mugellini, A | 1 |
| Destro, M | 1 |
| Corradi, L | 1 |
| Lazzari, P | 1 |
| Zoppi, A | 1 |
| Preti, P | 1 |
| Derosa, G | 1 |
| Ishida, K | 1 |
| Matsumoto, T | 3 |
| Taguchi, K | 3 |
| Kamata, K | 3 |
| Kobayashi, T | 3 |
| Nemoto, S | 1 |
| Garcia-Touza, M | 1 |
| Sowers, JR | 1 |
| Andersen, S | 2 |
| Rossing, P | 2 |
| Juhl, TR | 2 |
| Deinum, J | 1 |
| Kavgaci, H | 1 |
| Sahin, A | 1 |
| Onder Ersoz, H | 1 |
| Erem, C | 1 |
| Ozdemir, F | 1 |
| Jacobsen, P | 1 |
| Tarnow, L | 1 |
| Lu, WX | 1 |
| Lakkis, J | 1 |
| Weir, MR | 1 |
| McCall, AL | 1 |
| Nesto, RW | 1 |
| Suzuki, H | 2 |
| Kanno, Y | 1 |
| Kaneko, K | 1 |
| Kaneko, M | 1 |
| Kotaki, S | 1 |
| Mimura, T | 1 |
| Takane, H | 1 |
| Joshi, SR | 1 |
| Yeolekar, ME | 1 |
| Tripathi, KK | 1 |
| Giri, J | 1 |
| Maity, AK | 1 |
| Chopda, M | 1 |
| Gujarathi, S | 1 |
| Maroli, S | 1 |
| Maity, A | 1 |
| Higashiura, K | 1 |
| Shimamoto, K | 1 |
| Yasuda, G | 1 |
| Ando, D | 1 |
| Hirawa, N | 1 |
| Umemura, S | 1 |
| Tochikubo, O | 1 |
| Burnier, M | 1 |
| Zanchi, A | 1 |
| Liu, X | 1 |
| Sethi, R | 1 |
| Tappia, PS | 1 |
| Takeda, N | 1 |
| Dhalla, NS | 1 |
| Raz, I | 1 |
| Lee, YJ | 1 |
| Chiang, YF | 1 |
| Tsai, JC | 1 |
| Lozano, JV | 1 |
| Llisterri, JL | 1 |
| Aznar, J | 1 |
| Redon, J | 1 |
| Esmatjes, E | 1 |
| Flores, L | 1 |
| Iñigo, P | 1 |
| Lario, S | 1 |
| Ruilope, LM | 2 |
| Campistol, JM | 1 |
| Schnack, C | 1 |
| Schernthaner, G | 1 |
| Brenner, BM | 1 |
| Cooper, ME | 2 |
| Keane, WF | 1 |
| Mitch, WE | 1 |
| Snapinn, SM | 1 |
| Zhang, Z | 1 |
| Shahinfar, S | 1 |
| Dell'Italia, LJ | 1 |
| Rocic, P | 1 |
| Lucchesi, PA | 1 |
| de Pablos-Velasco, PL | 1 |
| Pazos Toral, F | 1 |
| Esmatjes, JE | 1 |
| Fernandez-Vega, F | 1 |
| Lopez de la Torre, ML | 1 |
| Pozuelo, A | 1 |
| Houlihan, CA | 1 |
| Akdeniz, A | 1 |
| Tsalamandris, C | 1 |
| Jerums, G | 1 |
| Gilbert, RE | 1 |
| Studney, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy[NCT00295555] | Phase 4 | 98 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Angiotensin Converting Enzyme Inhibitors & Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department.[NCT00437775] | 300 participants | Observational | 2007-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for losartan and Diabetic Angiopathies
| Article | Year |
|---|---|
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
Evidence-based hypertension treatment in patients with diabetes.
Topics: Albuminuria; Antihypertensive Agents; Diabetic Angiopathies; Diabetic Nephropathies; Endothelium, Va | 2012 |
Optimizing target-organ protection in patients with diabetes mellitus: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers?
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2003 |
Pharmacological treatment and prevention of heart failure in the diabetic patient.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diab | 2004 |
[Progress on the drug therapy for diabetic microangiopathies: RA system inhibitor].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2005 |
Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compound | 2006 |
[Angiotensin II type-1 receptor antagonists and diabetes mellitus].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
15 trials available for losartan and Diabetic Angiopathies
| Article | Year |
|---|---|
In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Comorbidity; Diabetes Mellitus, Type 2; D | 2013 |
Long-term hemodynamic and molecular effects persist after discontinued renin-angiotensin system blockade in patients with type 1 diabetes mellitus.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chemokines | 2013 |
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mel | 2015 |
Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2012 |
The effects of losartan and fosinopril in hypertensive type 2 diabetic patients.
Topics: Adult; Alanine Transaminase; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspa | 2002 |
Reducing CVD risk in type 2 DM.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type | 2004 |
Evaluation of efficacy and tolerability of Losartan and Ramipril combination in the management of hypertensive patients with associated diabetes mellitus in India (LORD Trial).
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Comorbidity; Diabetic Angiopathies; Drug Combi | 2004 |
Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy.
Topics: Adult; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, | 2005 |
Severe nonproductive cough and cough-induced stress urinary incontinence in diabetic postmenopausal women treated with ACE inhibitor.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cough; Diabetic Angiopathies; Double-Blind Method; Female; | 2000 |
Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics.
Topics: Albuminuria; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, | 2001 |
Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2001 |
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Topics: Adult; Aged; Angiotensin II; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Ty | 2001 |
Losartan titration versus diuretic combination in type 2 diabetic patients.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellit | 2002 |
Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction.
Topics: Albuminuria; Analysis of Variance; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood | 2002 |
11 other studies available for losartan and Diabetic Angiopathies
| Article | Year |
|---|---|
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compo | 2013 |
Intensive diabetes management for high-risk patients: how best to deliver?
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Delivery of Health Ca | 2009 |
A consistency-adjusted alpha-adaptive strategy for sequential testing.
Topics: Algorithms; Biostatistics; Captopril; Clinical Trials as Topic; Data Interpretation, Statistical; Di | 2010 |
Mechanisms underlying altered extracellular nucleotide-induced contractions in mesenteric arteries from rats in later-stage type 2 diabetes: effect of ANG II type 1 receptor antagonism.
Topics: Adenosine Triphosphate; Angiotensin II Type 1 Receptor Blockers; Animals; Cyclooxygenase 1; Cyclooxy | 2011 |
Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blocker | 2011 |
Angiotensin II type 2 receptor-dependent increase in nitric oxide synthase activity in the endothelium of db/db mice is mediated via a MEK pathway.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Diabetes Mellitus, Type 2; | 2012 |
Optimal dose of losartan for renoprotection in diabetic nephropathy.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetic Angiopathies; Diabetic Nephropathies; | 2002 |
Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Type 1; | 2003 |
Blockade of the renin-angiotensin system attenuates sarcolemma and sarcoplasmic reticulum remodeling in chronic diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Diabetic Angiopa | 2006 |
Albuminuria: a great risk marker, but an underestimated target in diabetes.
Topics: Albuminuria; Antihypertensive Agents; Biomarkers; Diabetes Mellitus; Diabetic Angiopathies; Humans; | 2008 |
Use of angiotensin-converting enzyme inhibitors in patients with diabetes and coronary artery disease.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bradykinin; Chyma | 2002 |